206 related articles for article (PubMed ID: 29329638)
1. Role of the IL-33/ST2L axis in colorectal cancer progression.
Akimoto M; Takenaga K
Cell Immunol; 2019 Sep; 343():103740. PubMed ID: 29329638
[TBL] [Abstract][Full Text] [Related]
2. ST2 Signaling in the Tumor Microenvironment.
Chang CP; Hu MH; Hsiao YP; Wang YC
Adv Exp Med Biol; 2020; 1240():83-93. PubMed ID: 32060890
[TBL] [Abstract][Full Text] [Related]
3. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment.
Akimoto M; Maruyama R; Takamaru H; Ochiya T; Takenaga K
Nat Commun; 2016 Nov; 7():13589. PubMed ID: 27882929
[TBL] [Abstract][Full Text] [Related]
4. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans.
Pusceddu I; Dieplinger B; Mueller T
Clin Chim Acta; 2019 Aug; 495():493-500. PubMed ID: 31136737
[TBL] [Abstract][Full Text] [Related]
5. Cancer cell-derived interleukin-33 decoy receptor sST2 enhances orthotopic tumor growth in a murine pancreatic cancer model.
Takenaga K; Akimoto M; Koshikawa N; Nagase H
PLoS One; 2020; 15(4):e0232230. PubMed ID: 32340025
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 33/ST2 Axis Components Are Associated to Desmoplasia, a Metastasis-Related Factor in Colorectal Cancer.
Landskron G; De la Fuente López M; Dubois-Camacho K; Díaz-Jiménez D; Orellana-Serradell O; Romero D; Sepúlveda SA; Salazar C; Parada-Venegas D; Quera R; Simian D; González MJ; López-Köstner F; Kronberg U; Abedrapo M; Gallegos I; Contreras HR; Peña C; Díaz-Araya G; Roa JC; Hermoso MA
Front Immunol; 2019; 10():1394. PubMed ID: 31281317
[TBL] [Abstract][Full Text] [Related]
7. The role of IL-33/ST2L signals in the immune cells.
Lu J; Kang J; Zhang C; Zhang X
Immunol Lett; 2015 Mar; 164(1):11-7. PubMed ID: 25662624
[TBL] [Abstract][Full Text] [Related]
8. IL-33 Promotes the Development of Colorectal Cancer Through Inducing Tumor-Infiltrating ST2L
Zhou Y; Ji Y; Wang H; Zhang H; Zhou H
Technol Cancer Res Treat; 2018 Jan; 17():1533033818780091. PubMed ID: 29950152
[TBL] [Abstract][Full Text] [Related]
9. Dynamic observation of IL-33 and its receptors in HIV patients who received HAART.
He B; Zheng L; Zhou H; He Y; Chen Z; Xiao S; Wang H; Ling Y; Zheng Y
Cell Mol Biol (Noisy-le-grand); 2017 Mar; 63(3):73-77. PubMed ID: 28466817
[TBL] [Abstract][Full Text] [Related]
10. IL-13 Controls IL-33 Activity through Modulation of ST2.
Zhang M; Duffen JL; Nocka KH; Kasaian MT
J Immunol; 2021 Dec; 207(12):3070-3080. PubMed ID: 34789557
[TBL] [Abstract][Full Text] [Related]
11. The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-α/IL-33/ST2L signaling promotes gastric cancer metastasis.
Zhou Q; Wu X; Wang X; Yu Z; Pan T; Li Z; Chang X; Jin Z; Li J; Zhu Z; Liu B; Su L
Oncogene; 2020 Feb; 39(7):1414-1428. PubMed ID: 31659258
[TBL] [Abstract][Full Text] [Related]
12. ST2 and regulatory T cells in the colorectal adenoma/carcinoma microenvironment: implications for diseases progression and prognosis.
Cui G; Yuan A; Li Z; Goll R; Florholmen J
Sci Rep; 2020 Apr; 10(1):5892. PubMed ID: 32246094
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia induces downregulation of the tumor-suppressive sST2 in colorectal cancer cells via the HIF-nuclear IL-33-GATA3 pathway.
Akimoto M; Susa T; Okudaira N; Koshikawa N; Hisaki H; Iizuka M; Okinaga H; Takenaga K; Okazaki T; Tamamori-Adachi M
Proc Natl Acad Sci U S A; 2023 May; 120(18):e2218033120. PubMed ID: 37094129
[TBL] [Abstract][Full Text] [Related]
14. Soluble ST2: A complex and diverse role in several diseases.
Homsak E; Gruson D
Clin Chim Acta; 2020 Aug; 507():75-87. PubMed ID: 32305537
[TBL] [Abstract][Full Text] [Related]
15. The IL-33/ST2 axis: Role in health and disease.
De la Fuente M; MacDonald TT; Hermoso MA
Cytokine Growth Factor Rev; 2015 Dec; 26(6):615-23. PubMed ID: 26271893
[TBL] [Abstract][Full Text] [Related]
16. IL-33 and Its Receptor ST2 after Inhaled Allergen Challenge in Allergic Asthmatics.
Mitchell PD; Salter BM; Oliveria JP; El-Gammal A; Tworek D; Smith SG; Sehmi R; Gauvreau GM; O Apos Byrne PM
Int Arch Allergy Immunol; 2018; 176(2):133-142. PubMed ID: 29694974
[TBL] [Abstract][Full Text] [Related]
17. An antitumorigenic role for the IL-33 receptor, ST2L, in colon cancer.
O'Donnell C; Mahmoud A; Keane J; Murphy C; White D; Carey S; O'Riordain M; Bennett MW; Brint E; Houston A
Br J Cancer; 2016 Jan; 114(1):37-43. PubMed ID: 26679377
[TBL] [Abstract][Full Text] [Related]
18. The biology of ST2: the International ST2 Consensus Panel.
Pascual-Figal DA; Januzzi JL
Am J Cardiol; 2015 Apr; 115(7 Suppl):3B-7B. PubMed ID: 25665766
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease.
Beltrán CJ; Núñez LE; Díaz-Jiménez D; Farfan N; Candia E; Heine C; López F; González MJ; Quera R; Hermoso MA
Inflamm Bowel Dis; 2010 Jul; 16(7):1097-107. PubMed ID: 20014018
[TBL] [Abstract][Full Text] [Related]
20. Soluble ST2 suppresses IL-5 production by human basophilic KU812 cells, induced by epithelial cell-derived IL-33.
Matsumoto K; Kouzaki H; Kikuoka H; Kato T; Tojima I; Shimizu S; Shimizu T
Allergol Int; 2018 Sep; 67S():S32-S37. PubMed ID: 29941231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
